grant

LMO1 intracellular antibody fragments for delivery in improved treatment of childhood neuroblastoma

Organization UKRILocation United Kingdom
UKRIUK ResearchGrantActive
Sign up free to applyApply link · pipeline · email alerts
— or —

Get email alerts for similar roles

Weekly digest · no password needed · unsubscribe any time

Description preview

The LIM-only protein LMO1 is implicated in neuroblastoma by synergising with MYCN to promote tumour development and metastasis. The proposed work will use technologies we developed to isolate an inhibitory intracellular antibody and, in turn Antibody-derived (Abd) compounds, for the LMO1 paralogue LMO2. The anti-LMO1 intracellular antibody will be…

🔒

Full details available on the Agency plan

Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.

Start 7-day free trial — $29.99/mo →

Agency Plan

7-day free trial

Unlock procurement & grants

Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.

$29.99 / month

  • 🔔Email alerts for new matching tenders
  • 🗂️Track tenders in your pipeline
  • 💰Filter by contract value
  • 📥Export results to CSV
  • 📌Save searches with one click
Start 7-day free trial →

Explore more

📍 More grants in United Kingdom🏷 More UKRI opportunities🏷 More UK Research opportunities🏷 More Grant opportunities🏢 All ukri_grants opportunities
LMO1 intracellular antibody fragments for delivery in improved treatment of childhood neuroblastoma — UKRI | United King | Dev Procure